{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:40:02Z","timestamp":1784227202670,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>A simple, fast and highly sensitive RP-UPLC-MS\/MS method was developed and validated for the simultaneous determination of sofosbuvir (SR) and its metabolite GS331007 in human plasma using ketotifen as an internal standard (IS). The separation was achieved on Acquity UPLC BEH C18 (50 \u00d7 2.1 mm, i.d. 1.7 \u00b5m, Waters, USA) column using acetonitrile:5 mM ammonium formate:0.1% formic acid (85:15:0.1% v\/v\/v) as a mobile phase at a flow rate of 0.35 mL\/min in an isocratic elution. The Xevo TQD UPLC-MS\/MS was operated under the multiple-reaction monitoring mode using positive electrospray ionization. Extraction with dichloromethane was used in the sample preparation. Method validation was performed as per the Food and Drug Administration (FDA) guidelines and the calibration curves of the proposed method were found to be linear in the range of 1\u20131000 ng\/mL for SR and in the range of 10\u20131500 ng\/mL for its metabolite (GS331007) with an elution time of 1.83 min. All validation parameters were within the acceptable range according to the bioanalytical methods validation guidelines. Furthermore, the obtained results of matrix effects indicate that ion suppression or enhancement from human plasma components was negligible under the optimized conditions. The proposed method can be applied in high-throughput analysis required for pharmacokinetic and bioequivalence studies in human samples.<\/jats:p>","DOI":"10.3390\/molecules24071302","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T03:13:42Z","timestamp":1554347622000},"page":"1302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quick and Sensitive UPLC-ESI-MS\/MS Method for Simultaneous Estimation of Sofosbuvir and Its Metabolite in Human Plasma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-7538","authenticated-orcid":false,"given":"Mohammad H.","family":"Semreen","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Sharjah, P.O. Box 27272, Sharjah, UAE"},{"name":"Sharjah Institute for Medical Research, University of Sharjah, P.O. Box 27272, Sharjah, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-9531","authenticated-orcid":false,"given":"Hasan Y.","family":"Alniss","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Sharjah, P.O. Box 27272, Sharjah, UAE"},{"name":"Sharjah Institute for Medical Research, University of Sharjah, P.O. Box 27272, Sharjah, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath K.","family":"Mousa","sequence":"additional","affiliation":[{"name":"Research Institute of Science and Engineering, University of Sharjah, P.O. Box 27272, Sharjah, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-7009","authenticated-orcid":false,"given":"Hassan Y.","family":"Aboul-Enein","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Medicinal Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, P.O. Box 12622, Dokki, Giza, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40265-014-0179-7","article-title":"Sofosbuvir: First global approval","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1060028014534194","article-title":"Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection","volume":"48","author":"Rose","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_3","first-page":"331","article-title":"Sofosbuvir: A novel oral agent for chronic hepatitis C","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Ann. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1021\/jm040068f","article-title":"Structure-activity relationship of heterobase-modified 2\u2032-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication","volume":"47","author":"Eldrup","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"388","article-title":"Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era","volume":"72","author":"Berden","year":"2014","journal-title":"Neth. J. Med."},{"key":"ref_9","first-page":"345","article-title":"Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection","volume":"39","author":"Cha","year":"2014","journal-title":"Pharm. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FTD.0000000000000567","article-title":"Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients","volume":"41","author":"Schrezenmeier","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jchromb.2017.12.018","article-title":"UPLC-MS\/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV\/HCV co-infected patients","volume":"1073","author":"Notari","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jpba.2017.06.005","article-title":"Development a validated highly sensitive LC-MS\/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study","volume":"143","author":"Abdallah","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2015.05.006","article-title":"Development of a sensitive UPLC-ESI-MS\/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study","volume":"114","author":"Rezk","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchromb.2015.08.038","article-title":"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS\/MS","volume":"1002","author":"Shi","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jpba.2015.08.023","article-title":"Rapid, sensitive and selective HPLC-MS\/MS method for the quantification of topically applied besifloxacin in rabbit plasma and ocular tissues: Application to a pharmacokinetic study","volume":"117","author":"Gu","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jchromb.2015.11.056","article-title":"Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS\/MS and its application to a pharmacokinetic study","volume":"1008","author":"Pan","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jsps.2018.05.011","article-title":"Quantitative determination of doxorubicin in the exosomes of A549\/MCF-7 cancer cells and human plasma using ultra performance liquid chromatography-tandem mass spectrometry","volume":"26","author":"Semreen","year":"2018","journal-title":"Saudi Pharm. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4155\/bio.13.298","article-title":"New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: Chromatographic methods and ISR","volume":"6","author":"Zimmer","year":"2014","journal-title":"Bioanalysis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1044-0305(03)00574-9","article-title":"Matrix effect in bio-analysis of illicit drugs with LC-MS\/MS: Influence of ionization type, sample preparation, and biofluid","volume":"14","author":"Dams","year":"2003","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jchromb.2009.01.003","article-title":"Validation of bioanalytical LC-MS\/MS assays: Evaluation of matrix effects","volume":"877","author":"Lanckmans","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/7\/1302\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:33Z","timestamp":1760186553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/7\/1302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["molecules24071302"],"URL":"https:\/\/doi.org\/10.3390\/molecules24071302","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]}}}